Published in J Immunol Methods on January 01, 1980
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol (1998) 3.65
Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J (1987) 2.31
Adsorption of fibronectin onto polymethylmethacrylate and promotion of Staphylococcus aureus adherence. Infect Immun (1984) 1.86
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol (1987) 1.68
Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol (1986) 1.37
In vitro parasite-monocyte interactions in human leishmaniasis: possible role of fibronectin in parasite attachment. Infect Immun (1985) 1.21
Models of fibronectin. EMBO J (1987) 0.94
Species-specific monoclonal antibodies in the assignment of the gene for human fibronectin to chromosome 2. EMBO J (1982) 0.91
Human plasma fibronectin. Demonstration of structural differences between the A- and B-chains in the III CS region. Biochem J (1991) 0.85
Surface proteins in normal and transformed rat liver epithelial cells in culture. Br J Cancer (1980) 0.75
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet (1997) 6.99
Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal Biochem (1979) 5.67
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol (1998) 3.65
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst (1999) 2.90
Molecular Probe Database: a database on synthetic oligonucleotides. Nucleic Acids Res (1992) 2.79
Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut (2009) 2.75
bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol (1997) 2.66
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol (2001) 2.42
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst (1996) 2.41
Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J (1987) 2.31
p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol (2001) 2.19
Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst (1991) 2.15
Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. J Pathol (1993) 2.12
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem (1997) 2.09
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med (2004) 1.89
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol (1997) 1.85
Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem (1998) 1.83
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol (2012) 1.69
Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol (1987) 1.68
Outcome of special types of luminal breast cancer. Ann Oncol (2011) 1.67
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett (1988) 1.61
Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer (2001) 1.60
Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci (1987) 1.60
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer (1998) 1.58
Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord (1996) 1.58
Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med (2001) 1.57
Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer (2003) 1.55
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med (1998) 1.53
Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol (1996) 1.52
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer (1994) 1.51
Elution of fibronectin proteolytic fragments from a hydroxyapatite chromatography column. A simple procedure for the purification of fibronectin domains. Eur J Biochem (1985) 1.51
Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol (2011) 1.50
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol (2010) 1.47
Quality indicators in breast cancer care. Eur J Cancer (2010) 1.46
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol (2014) 1.45
The problem of the accuracy of intraoperative examination of axillary sentinel nodes in breast cancer. Ann Surg Oncol (2001) 1.45
Expression of emmprin by oral squamous cell carcinoma. Int J Cancer (2000) 1.42
In vitro interactions between barley TALE homeodomain proteins suggest a role for protein-protein associations in the regulation of Knox gene function. Plant J (2001) 1.41
Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat (2009) 1.41
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Immunoreactivity for latent membrane protein 1 of Epstein-Barr virus in nevi and melanomas is not related to the viral infection. Virchows Arch (2000) 1.39
Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res (1995) 1.39
Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol (1986) 1.37
CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood (1996) 1.35
Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst (1994) 1.35
Differences in domain structure between human fibronectins isolated from plasma and from culture supernatants of normal and transformed fibroblasts. Studies with domain-specific antibodies. J Biol Chem (1985) 1.34
p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol (1995) 1.32
Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids Res (1991) 1.31
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol (2006) 1.29
Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett (1990) 1.28
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
Fibronectin: a chromatin-associated protein? Cell (1979) 1.25
DNA damage induced by auramine O in liver, kidney, and bone marrow of rats and mice, and in a human cell line (alkaline elution assay and SCE induction). J Toxicol Environ Health (1982) 1.24
Localization of the cellular-fibronectin-specific epitope recognized by the monoclonal antibody IST-9 using fusion proteins expressed in E. coli. FEBS Lett (1987) 1.24
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer (1994) 1.23
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol (2008) 1.23
Fetal myofibroblast-like cells isolated from post-radiation fibrosis in human breast cancer. Int J Cancer (1991) 1.22
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
Comparison of radioguided excision with wire localization of occult breast lesions. Br J Surg (1999) 1.22
Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature. Mod Pathol (2001) 1.22
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res (2001) 1.21
bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol (1995) 1.21
Managing patients with lung cancer. Common international guidelines must be developed. BMJ (2000) 1.20
Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem (1996) 1.19
Plasma and urinary levels of adriamycin in man. Eur J Cancer (1972) 1.19
Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem (1995) 1.19
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol (2012) 1.19
Mortality among shipyard workers in Genoa, Italy. Ann N Y Acad Sci (1979) 1.18